Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company ...

The firm has made significant strides in its RNA editing and RNA interference programs, which are attracting positive attention and positioning the company for differentiation in the treatment of ...

Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

Our best-in-class RNA platform is consistently translating in the clinic and demonstrating how we can uniquely design, and ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

Alongside a new lab, MI:RNA has appointed Judy Keator as head of global business development. She has more than 22 years’ ...

Phlox Therapeutics is developing Ribonucleic acid (RNA)-based gene therapies to treat cardiomyopathies, disorders that affect the heart muscle.